Skip to content

Released Mar 5, 2025, after the close

10-K filed Mar 5, 2025, 64 days after period end · 0000950170-25-033510

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$1.86Mderived+11.0% vs Q4 2023−39.5% vs Q3 2024
Net Income-$52.15MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$61,748,000N/M
Operating Cash Flowderived-$27,799,000N/M
Free Cash Flowderived-$27,897,000N/M
Margins · derived
Operating margin-3319.8%−451.3 pt vs Q4 2023
Net margin-2803.9%−171.3 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$1.86M$1.68M$44.36M$17.07M
Net Income-$52.15M-$44.12M-$56.36M-$68.62M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR